FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379468461> ?p ?o ?g. }

• W4379468461 endingPage "22522" @default.
• W4379468461 startingPage "22508" @default.
• W4379468461 abstract "There is an increasing prevalence of diabetes mellitus throughout the world, and new compounds are necessary to combat this. The currently available antidiabetic therapies are long-term complicated and side effect-prone, and this has led to a demand for more affordable and more effective methods of tackling diabetes. Research is focused on finding alternative medicinal remedies with significant antidiabetic efficacy as well as low adverse effects. In this research work, we have focused our efforts to synthesize a series of 1,2,4-triazole-based bis-hydrazones and evaluated their antidiabetic properties. In addition, the precise structures of the synthesized derivatives were confirmed with the help of various spectroscopic techniques including 1H-NMR, 13C-NMR, and HREI-MS. To find the antidiabetic potentials of the synthesized compounds, in vitro α-glucosidase and α-amylase inhibitory activities were characterized using acarbose as the reference standard. From structure-activity (SAR) analysis, it was confirmed that any variation found in inhibitory activities of both α-amylase and α-glucosidase enzymes was due to the different substitution patterns of the substituent(s) at variable positions of both aryl rings A and B. The results of the antidiabetic assay were very encouraging and showed moderate to good inhibitory potentials with IC50 values ranging from 0.70 ± 0.05 to 35.70 ± 0.80 μM (α-amylase) and 1.10 ± 0.05 to 30.40 ± 0.70 μM (α-glucosidase). The obtained results were compared to those of the standard acarbose drug (IC50 = 10.30 ± 0.20 μM for α-amylase and IC50 = 9.80 ± 0.20 μM for α-glucosidase). Specifically, compounds 17, 15, and 16 were found to be significantly active with IC50 values of 0.70 ± 0.05, 1.80 ± 0.10, and 2.10 ± 0.10 μM against α-amylase and 1.10 ± 0.05, 1.50 ± 0.05, and 1.70 ± 0.10 μM against α-glucosidase, respectively. These findings reveal that triazole-containing bis-hydrazones act as α-amylase and α-glucosidase inhibitors, which help develop novel therapeutics for treating type-II diabetes mellitus and can act as lead molecules in drug discovery as potential antidiabetic agents." @default.
• W4379468461 created "2023-06-07" @default.
• W4379468461 creator A5016781101 @default.
• W4379468461 creator A5021032200 @default.
• W4379468461 creator A5024299937 @default.
• W4379468461 creator A5025167574 @default.
• W4379468461 creator A5054768783 @default.
• W4379468461 creator A5069001346 @default.
• W4379468461 creator A5073391774 @default.
• W4379468461 creator A5074589101 @default.
• W4379468461 creator A5086422606 @default.
• W4379468461 date "2023-06-05" @default.
• W4379468461 modified "2023-10-17" @default.
• W4379468461 title "Synthesis and In Vitro α-Amylase and α-Glucosidase Dual Inhibitory Activities of 1,2,4-Triazole-Bearing <i>bis</i>-Hydrazone Derivatives and Their Molecular Docking Study" @default.
• W4379468461 cites W1174807774 @default.
• W4379468461 cites W1786884398 @default.
• W4379468461 cites W1965933256 @default.
• W4379468461 cites W1968238235 @default.
• W4379468461 cites W1973963032 @default.
• W4379468461 cites W1977109526 @default.
• W4379468461 cites W1997477595 @default.
• W4379468461 cites W2003579943 @default.
• W4379468461 cites W2006522535 @default.
• W4379468461 cites W2022687771 @default.
• W4379468461 cites W2036167841 @default.
• W4379468461 cites W2043969520 @default.
• W4379468461 cites W2059067578 @default.
• W4379468461 cites W2063356237 @default.
• W4379468461 cites W2070032322 @default.
• W4379468461 cites W2078320157 @default.
• W4379468461 cites W2086685211 @default.
• W4379468461 cites W2093243013 @default.
• W4379468461 cites W2097365404 @default.
• W4379468461 cites W2097600350 @default.
• W4379468461 cites W2118458879 @default.
• W4379468461 cites W2124772160 @default.
• W4379468461 cites W2139698840 @default.
• W4379468461 cites W2149960743 @default.
• W4379468461 cites W2258221372 @default.
• W4379468461 cites W2284437534 @default.
• W4379468461 cites W2342534600 @default.
• W4379468461 cites W2416937488 @default.
• W4379468461 cites W2418178572 @default.
• W4379468461 cites W2460062919 @default.
• W4379468461 cites W2505843028 @default.
• W4379468461 cites W2595724486 @default.
• W4379468461 cites W2606178383 @default.
• W4379468461 cites W2734937587 @default.
• W4379468461 cites W2737953027 @default.
• W4379468461 cites W2742338598 @default.
• W4379468461 cites W2765227482 @default.
• W4379468461 cites W2770086810 @default.
• W4379468461 cites W2770376431 @default.
• W4379468461 cites W2962983903 @default.
• W4379468461 cites W2982084620 @default.
• W4379468461 cites W2999315716 @default.
• W4379468461 cites W3011959076 @default.
• W4379468461 cites W3014756783 @default.
• W4379468461 cites W3015064645 @default.
• W4379468461 cites W3081881108 @default.
• W4379468461 cites W3115611586 @default.
• W4379468461 cites W4296093968 @default.
• W4379468461 cites W4303856564 @default.
• W4379468461 cites W4312117194 @default.
• W4379468461 cites W857389971 @default.
• W4379468461 doi "https://doi.org/10.1021/acsomega.3c00702" @default.
• W4379468461 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37396210" @default.
• W4379468461 hasPublicationYear "2023" @default.
• W4379468461 type Work @default.
• W4379468461 citedByCount "1" @default.
• W4379468461 crossrefType "journal-article" @default.
• W4379468461 hasAuthorship W4379468461A5016781101 @default.
• W4379468461 hasAuthorship W4379468461A5021032200 @default.
• W4379468461 hasAuthorship W4379468461A5024299937 @default.
• W4379468461 hasAuthorship W4379468461A5025167574 @default.
• W4379468461 hasAuthorship W4379468461A5054768783 @default.
• W4379468461 hasAuthorship W4379468461A5069001346 @default.
• W4379468461 hasAuthorship W4379468461A5073391774 @default.
• W4379468461 hasAuthorship W4379468461A5074589101 @default.
• W4379468461 hasAuthorship W4379468461A5086422606 @default.
• W4379468461 hasBestOaLocation W43794684611 @default.
• W4379468461 hasConcept C159110408 @default.
• W4379468461 hasConcept C170835558 @default.
• W4379468461 hasConcept C178790620 @default.
• W4379468461 hasConcept C181199279 @default.
• W4379468461 hasConcept C185592680 @default.
• W4379468461 hasConcept C202751555 @default.
• W4379468461 hasConcept C21951064 @default.
• W4379468461 hasConcept C2776617576 @default.
• W4379468461 hasConcept C2777752497 @default.
• W4379468461 hasConcept C2778689049 @default.
• W4379468461 hasConcept C2780020378 @default.
• W4379468461 hasConcept C2780263894 @default.
• W4379468461 hasConcept C2780349576 @default.
• W4379468461 hasConcept C2781076698 @default.
• W4379468461 hasConcept C41685203 @default.
• W4379468461 hasConcept C55493867 @default.
• W4379468461 hasConcept C71240020 @default.

• next